Skip to main content

Table 1 A table showing the baseline demographics and initial treatment for each group

From: Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia

 

e13a2

e14a2

p value

Number

 %

29%

71.0%

n/a

 Exact

20

49

Age (years)

 Mean

45.0

54.57

0.043

 Median

46.0

59.0

 Range

4–81

5–80

Sex

 Male

75.0%

55.1%

0.125

 Female

25.0%

44.9%

Follow-up (months)

 Mean

33.85

27.24

0.192

 Median

37.5

23

 Range

1–70

3–76

Haemoglobin (g/l)

 Mean

113.5

121.3

0.134

 Range

86–148

64–158

White Cell Count

  (×109/l)

189.80

92.40

0.0002

 Mean

49.1–563

4.86–292

 Range

  

Platelets (×109/l)

 Mean

308

644

0.001

 Range

93–1058

178–2507

EUTOS SCORE

 Number available

15

42

0.685

 Average Score

35.93

39.66

 % High Risk

5.0%

6.1%

BCR-ABL1 PCR level

 Number available

17

42

0.354

 Mean

58.64%

71.0%

 Range

25.6–112

8.1–344

Initial Treatment

 Imatinib 400 mg/day

90%

93.9%

n/a

 Imatinib 300 mg/day

5%

0%

 Imatinib 200 mg/day

5%

6.1%